drugset / Trial / NCT01979939
UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To demonstrate the effectiveness of DCV 3DAA fixed dose regimen in treatment naive and treatment experienced non-cirrhotic subjects
Timeline
- Start
- 2013-12
- Primary completion
- 2014-08
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Asunaprevir | Small molecule | 200 mg | Oral |
| Subject | Beclabuvir | Small molecule | 75 mg | Oral |
| Subject | Daclatasvir | Small molecule | 30 mg | Oral |